Home
  >  
Section 10
  >  
Chapter 9,605

The oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats

Sadrzadeh, S.M.; Nanji, A.A.; Price, P.L.

Journal of Pharmacology and Experimental Therapeutics 269(2): 632-636

1994

ISSN/ISBN: 0022-3565
PMID: 8182529
Accession: 009604109
Download citation:  
Text
  |  
BibTeX
  |  
RIS
The effect of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on liver nonheme iron, lipid peroxidation and hepatic fat accumulation in the intragastric feeding rat model for alcoholic liver disease was studied. Male Wistar rats (225-250 g) were fed liquid diet and ethanol for 1 month. In control pair-fed animals, ethanol was replaced isocalorically by dextrose. Two additional groups of animals (dextrose and ethanol-fed) received L1 (75 mg/kg/day for 30 days). The blood ethanol level in the ethanol-fed animals was maintained between 150 and 350 mg/dl. For each animal, the levels of hepatic nonheme iron, lipid peroxidation and triglyceride were evaluated. The nonheme iron in alcohol-fed animals was significantly higher (416 +/- 15 nmol/g of liver) than in pair-fed dextrose controls (346 +/- 18.5 nmol/g, P < .05). Animals fed ethanol and L1 had significantly lower nonheme iron (364 +/- 9.3 nmol/g) than rats fed ethanol alone (P < .05). L1 had no effect on nonheme iron levels in dextrose-fed controls. The importance of iron in lipid peroxidation in this model is shown by the positive correlation between the nonheme iron levels and microsomal conjugated dienes (r = 0.67, P < .02) and liver thiobarbituric acid reactive substances (r = 0.62, P < .05). The most significant observations in this study were: 1) the higher hepatic nonheme iron content in ethanol-fed rats compared to pair-fed dextrose controls; 2) lower nonheme iron and liver fat in the ethanol-fed rats treated with L1; and 3) the significant positive correlation between the liver nonheme and lipid peroxidation.

PDF emailed within 1 workday: $29.90




Related References

Fassos, F.F.; Berkovitch, M.; Daneman, N.; Koren, L.; Cameron, R.; Klein, J.; Falcitelli, C.; St Louis, P.; Koren, G. 1995: Reduced iron accumulation in the organs of rats treated with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one following acute iron intoxication Clinical and Investigative Medicine 18(4 Suppl): B119
Venkataram, S.; Rahman, Y.E. 1990: Studies of an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one. I. Iron excretion in rats: development of a new rapid microwave method for iron analysis in faeces British Journal of Haematology 75(2): 274-277
Matsui, D.; Berkovitch, M.; Olivieri, N.; Koren, G.; Group, T.I.on Chelation Research 1994: Reduction in hepatic iron stories with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with transfusion dependent thalassemia Clinical Pharmacology and Therapeutics 55(2): 175
Fassos, F.F.; Berkovitch, M.; Daneman, N.; Koren, L.; Cameron, R.; Klein, J.; Falcitelli, C.; St Louis, P.; Koren, G. 1995: The oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one successfully prevents mortality following acute iron intoxication in rats Clinical and Investigative Medicine 18(4 Suppl): B21
Kontoghiorghes, G.J.; Sheppard, L.; Hoffbrand, A.V.; Charalambous, J.; Tikerpae, J.; Pippard, M.J. 1987: Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats Journal of Clinical Pathology 40(4): 404-408
Fassos, F.F.; Berkovitch, M.; Daneman, N.; Koren, L.; Cameron, R.; Klein, J.; Falcitelli, C.; St Louis, P.; Koren, G. 1995: The use of diazepam during the treatment of acute iron intoxication in rats, in the absence and presence of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one Clinical and Investigative Medicine 18(4 Suppl): B19
Collins, A.F.; Fassos, F.F.; Stobie, S.; Lewis, N.; Shaw, D.; Fry, M.; Templeton, D.M.; McClelland, R.A.; Koren, G.; Olivieri, N.F. 1994: Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease Blood 83(8): 2329-2333
Olivieri, N.F.; Templeton, D.M.; Koren, G.; Chung, D.; Hermann, C.; Freedman, M.H.; McClelland, R.A. 1990: Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients Annals of the new York Academy of Sciences 612: 369-377
Klein J.; Chung D.; Hermann C.; Matsui D.; St Louis P.; Olivieri N.; Koren G. 1991: Pharmacokinetics and iron excretion of a new oral iron chelator 1 2 dimethyl 3 hydroxypyrid 4 one l1 in thalassemic children Clinical Pharmacology and Therapeutics 49(2): 162
Kontoghiorghes, G.J.; Sheppard, L.N.; Barr, J.; Goddard, J.G.; Hoffbrand, A.V.; Bartlett, L.; Evans, R.W. 1991: Metabolic effects of the oral iron chelator 1 2 dimethyl 3 hydroxypyrid 4 one in human with normal iron stores European Journal of Clinical Investigation 21(2 Part 2): 57
Matsui, D.; Klein, J.; Hermann, C.; Grunau, V.; McClelland, R.; Chung, D.; St-Louis, P.; Olivieri, N.; Koren, G. 1991: Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia Clinical Pharmacology and Therapeutics 50(3): 294-298
Kontoghiorghes, G.J.; Bartlett, A.N.; Hoffbrand, A.V.; Goddard, J.G.; Sheppard, L.; Barr, J.; Nortey, P. 1990: Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies British Journal of Haematology 76(2): 295-300
al-Refaie, F.N.; Wonke, B.; Wickens, D.G.; Aydinok, Y.; Fielding, A.; Hoffbrand, A.V. 1994: Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine Journal of Clinical Pathology 47(7): 657-660
Vreugdenhil, G.; Swaak, A.J.; de Jeu-Jaspers, C.; van Eijk, H.G. 1990: Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis Annals of the Rheumatic Diseases 49(11): 956-957
Matsui, D.; Olivieri, N.; Berkovitch, M.; Templeton, D.; Wanless, I.; Blendis, L.; Liu, P.; Koren, G. 1993: Effective iron chelation using the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one , in homozygous beta-thalassemia major patients Clinical Pharmacology and Therapeutics 53(2): 145
Agarwal, M.B.; Gupte, S.S.; Vasandani, D.; Viswanathan, C.; Puniyani, R.R.; Ramanathan, J.; Massil, D.E.; Shah, S.; Rajyadhyaksha, G.C.; Bhave, A.A. 1991: Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload Journal of the Association of Physicians of India 39(9): 669-672
Fassos, F.F.; Klein, J.; Fernandes, D.; Matsui, D.; Olivieri, N.F.; Koren, G. 1994: Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia Clinical Pharmacology and Therapeutics 55(1): 70-75
Vreugdenhil, G.; Kontoghiorghes, G.J.; Van Eijk, H.G.; Swaak, A.J. 1991: Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. a possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one Clinical and Experimental Rheumatology 9(1): 35-40
Bentur, Y.; Klein, J.; Levy, M.; Olivieri, N.; Mcguigan, M.; Koren, G. 1989: 2 dimethyl 3 hydroxypyrid 4 one a new oral chelator in acute iron intoxication Veterinary and Human Toxicology 31(4): 336
Matsui, D.; Olivieri, N.; Koren, G.; Templeton, D.; Liu, P. 1992: Use of the new oral iron chelator 1 2 dimethyl 3 hydroxypyrid 4 one l1 in thalassemia patients Clinical and Investigative Medicine 15(4 Suppl): A21